A Company Focused on Improving Care for Patients with NASH/MASH

Clinical-stage Biopharmaceutical Company - Madrigal Pharmaceuticals

Madrigal is pursuing novel therapeutics that target NASH.

Madrigal is a biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH).

Madrigal has advanced its once daily, oral, liver-directed thyroid hormone receptor (THR) β-selective agonist, into multiple Phase 3 clinical trials in NASH. Based on Phase 3 results reported to date, the U.S. FDA granted accelerated approval for the therapy for the treatment of adults with NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).

NASH is a growing global health burden in all regions of the world, but many patients with NASH remain undiagnosed.

Madrigal has established the most advanced and comprehensive clinical development program in NASH.